Genmab — Juni 2023
-
EPCORE DLBCL-1 seems fully recruited. They are extending the duratoin of the trial by 4 years. Outcomes will now be measured for 5 years instead of the intended 2 years. How should i read this? Is this a requirement by the FDA? Or are they now thinking patients could still be active on Epco after 5 years instead of 2? https://classic.clinicaltrials.gov/ct2/history/NCT04628494?B=24&A=23&C=merged#StudyPageTop
-
Case report: Successful treatment with daratumumab for pure red cell aplasia in a patient with mixed lymphoid chimerism after ABO-mismatched stem cell transplant for sickle cell disease https://www.frontiersin.org/articles/10.3389/fimmu.2023.1212007/full?utm_source=S-TWT&utm_medium=SNET&utm_campaign=ECO_FIMMU_XXXXXXXX_auto-dlvrit
-
I hope you are right @Sukkeralf . I do believe interim data can be sufficient for filing
-
$XBI Big Biotech #Outflows Return
~$894M of net outflows
This is the #second #largest week of outflows for the sector this year and marks
the 19th week of outflows out of 25 total weeks in 2023. YTD net fund flow now stands
at ~$7.2B in outflows. https://twitter.com/BiotechAnalysst/status/1672236857281716225 -
Enig Riis.Tendensen er klart i den retning.
-
TEPEZZA
(teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED) https://ir.horizontherapeutics.com/news-releases/news-release-details/tepezzar-teprotumumab-approved-brazil-treatment-active-thyroid -
Adicet nede med 50% efter PH1 data i r/r B-cell NHL https://investor.adicetbio.com/news-releases/news-release-details/adicet-bio-reports-positive-data-ongoing-adi-001-phase-1-trial-0
-
Måske der ligger en forklaring i, at der skal rejses enorme beløb til gennemførsel af videre forløb. Udfra at have kastet et hurtigt blik på regnskabet, ser det ikke ud til
-
, at virksomheden p.overhovedet har haft nogen form for omsætning. NB- de der amerikanske regnskaber har jeg en smule besvær med at tyde. Det bliver jo ikke nemmere af, at den nominelle værdi af et stk. aktie udgør 0,00001$, så vidt jeg kan se
-
Godmorgen
-
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE
NHL-1 Trial Evaluating Epcoritamab (DuoBody CD3xCD2
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind